Skip to main content
Log in

Twice weekly vindesine, a phase II study in lung cancer

  • Short Communication
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Summary

Vindesine 1.75 mg/m2, twice weekly for 2 weeks followed by 2 weeks rest, was given to 26 lung cancer patients. In 6 patients a partial response was seen (23%). Neurotoxicity was present in 15 patients after 1 course; in 6 patients this was the reason for stopping therapy. This regimen has no advantage over weekly vindesine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  • Mulder NH, Postmus PE, Sleijfer DTh, de Vries EGE, Willemse PHB (1985) Phase one study of twice weekly vindesine. Eur J Cancer Clin Oncol 21:1555–1556

    Article  PubMed  Google Scholar 

  • Natale RB, Gralla RJ, Wittes R, Golbey R, Young C (1980) Vindesine chemotherapy in lung cancer. Cancer Treat Rev 7 (Suppl):59–63

    Google Scholar 

  • Osterlind K, Dombernowsky P, Sorensens PG, Hansen HH (1981) Vindesine in the treatment of small cell anaplastic bronchogenic carcinoma. Cancer Treat Rep 65:245–248

    PubMed  Google Scholar 

  • WHO Handbook for reporting results of cancer treatment WHO offset publication No 48 (1979) The Hague, Nyhoff

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Postmus, P.E., Mulder, N.H., Schipper, D.L. et al. Twice weekly vindesine, a phase II study in lung cancer. J Cancer Res Clin Oncol 113, 99–100 (1987). https://doi.org/10.1007/BF00389975

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00389975

Key words

Navigation